The efficacy of <scp>PD</scp> ‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study-Reference-Cited by-同舟云学术

The efficacy of PD ‐1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study

Published:2022-11-03 Issue:6 Volume:7 Page:1808-1813
ISSN:2378-8038
Container-title:Laryngoscope Investigative Otolaryngology
language:en
Short-container-title:Laryngoscope Investig Oto

Author:

Sato Ryosuke¹^ORCID,Kumai Takumi²³^ORCID,Ishida Yoshiya¹,Yuasa Ryota¹,Kubota Akinobu¹,Wakisaka Risa³,Komatsuda Hiroki³^ORCID,Yamaki Hidekiyo³,Wada Tetsuji¹,Harabuchi Yasuaki³

Affiliation:

1. Department of Otolaryngology Kitami Red Cross Hospital Kitami Japan

2. Department of Innovative Head & Neck Cancer Research and Treatment Asahikawa Medical University Asahikawa Japan

3. Department of Otolaryngology‐Head & Neck Surgery Asahikawa Medical University Asahikawa Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/lio2.863

Reference16 articles.

1. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

2. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

4. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma

5. Diagnosis and Management of Malignant Salivary Gland Tumors of the Parotid Gland

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation of salivary gland function due to cancer therapy;Oral Diseases;2024-05-02

2. Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma;Journal of Immunotherapy;2024-03-28

3. Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers;Cancers;2024-03-19

4. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study;ORL;2023-12-13